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ABSTRACT
PurPose: locally advanced rectal cancer (lArC) represents approximately 10% of all colorectal cancers. 
The achievement of r0 resection through multidisciplinary approach combining chemoradiotherapy and 
aggressive surgery as total or posterior pelvic exenteration is the only curative option for these patients. The 
preservation of the pelvic diaphragm is associated with considerably higher quality of life.  
MATerIAl ANd MeTHods: A total of 13 patients with lArC were treated by the authors from 2008 to 
2012. All of them underwent neoadjuvant chemoradiotherapy and followed-up by CT, MrI and colonosco-
py for a mean period of 35 months. early complication and recurrence rates were recorded. Two cases with 
sphincter preserving total pelvic exenteration (TPe) were presented in details. 
resulTs: eleven posterior (PPe) and two TPr with preservation of urogenital and anal sphincters were 
performed. Clear oncologic margins were achieved in 11 patients. There were no cases with distant metasta-
ses. The two cases with total exenteration are still alive and cancer-free, 18 and 13 months after the opera-
tion, respectively. The mean survival is 20,5 months as the follow-up is still ongoing.
CoNClusIoN: The multimodal approach including pelvic exenteration surgery is the only curative option 
for the patients with locally advanced rectal carcinoma. The survival strongly correlates with the disease-
free interval, so the achievement of r0 resection is mandatory. The primary lArCs are associated with low-
er morbidity and better survival rates than the recurrences. The preservation of the pelvic diaphragm, when 
possible, is very important for achievement of better quality of life.
Key words: locally advanced rectal cancer, minor pelvic exenteration, quality of life, local recurrence, case 
reports 
INTRODuCTION 
Locally advanced rectal cancer (LARC) without 
distant spreading represents approximately 10% of 
all colorectal cancers. If left untreated, it has a poor 
prognosis. Because of the relatively slow progression 
the death usually occurs whitin two years for primary 
and one year for recurrent rectal carcinoma (15). 
Severe pain and septic complications significantly 
worsen the quality of life (qoL) of these patients. The 
multidisciplinary approach with chemoradiotherapy 
combined with total or posterior (for women) pelvic 
exenteration (TPE/PPE) is the only curative option 
for them. 
The achievement of satisfactory qoL becomes 
very important aspect of the modern surgery, besides 
the improved survival. A step in this direction 
for these patients is the preservation of the pelvic 
diaphragm with the sphincters, when possible, and 
one-stage or a later restoration at least of one of the 
both tracts (7,11).
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MATERIAL AND METHODS
A total of 13 patients with LARC were treated by 
the authors from 2008 to 2012. All of them underwent 
neoadjuvant chemoradiotherapy. They were followed-
up by CT, magnetic resonance imaging (MRI) and 
colonoscopy for a mean period of 35 months. Early 
complication and recurrence rates were recorded. 
The two cases with sphincter preserving TPE were 
presented in details. Additionally, a brief review of 
the published results in the period 2000-2012 was 
performed.
CASE REPORTS
Both patients were males with LARC engaging 
the urinary bladder. The indications for TPE were the 
lack of distant metastases and sepsis due to the com-
munication between digestive and urinary tracts. In 
both of them, TPE with preservation of the urogen-
ital diaphragm and anal sphincters was performed.
The first case was a 51-year-old male with ad-
vanced rectal carcinoma engaging the whole circum-
ference of the rectum, extending from the anorectal 
junction to 9 cm proximally. MRI revealed an infil-
tration of the urinary bladder. The subsequent cys-
toscopy revealed infiltration of the trigonum and 
ureter’s orifices bilaterally. Neoadjuvant radiothera-
py with cobalt was performed (25x2 Gy). The follow-
up contrast MRI after 73 days revealed progression of 
tumour size from 83/58 mm to 97/51 mm with a large 
engagement of the perirectal adipose tissue, seminal 
vesicles and the posterior wall of the bladder with a 
rectovesical fistula (Figs. 1 and 2). on physical ex-
amination, a circular fixed tumour was found with a 
leakage of urine. The laboratory results were normal 
except for hemoglobin level of 8,6 mg/dL.
Intraoperatively, tumour of the rectum with 
a large infiltration of the posterior wall of the uri-
nary bladder was found proven by biopsy of the tri-
gonum. Due to lack of infiltration of the urogenital 
diaphragm and achievement of 3 cm distal clearance 
TPE was performed with blood loss of 1800 mL (Fig. 
3). The left ureter was anastomosed with the right 
one, which was brought out as ureterocutaneosto-
my on the right side of the anterior abdominal wall 
and sigmostomy was performed. The patient had 
uneventful recovery and was discharged on the 12th 
postoperative day.
The gross examination of the specimen revealed 
tumour size of 18/8 cm with infiltration of the urinary 
bladder and presence of fistula (Fig. 4). A microscopic 
examination showed G1 adenocarcinoma pT4bN0M0 
(0/12). All resectional margins, prostate gland, 12 
perirectal and 3 mesenterial lymph nodes were 
fig. 1. follow-up Mri (axial view) clearly demonstrates 
the presence of a rectovesical fistula - the bladder contrast 
passing into the rectum. Tumour size is 97/51 mm
fig. 2. follow-up Mri (sagittal view) shows the 
infiltration of prostate and posterior wall of the urinary 
bladder. Tumour size is 83/58 mm 
fig. 3. intraoperative view after TPe with preserved 
urogenital diaphragm. Both ureters are resected and 
cannulated (see the bottom of the picture)
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free of carcinoma (R0 resection). one year after the 
operation, the patient had no recurrence (based on 
MRI and colonoscopy) and underwent restoration of 
the integrity of gastrointestinal tract.
The second patient was a 70-year-old male with 
LARC engaging the entire circumference from the 5th 
to the 12th cm from the dentate line and infiltration 
of the posterior bladder wall. After sigmostomy and 
neoadjuvant radiotherapy, TPE was performed two 
months later on. He had uneventful recovery and 
was discharged on the 10th postoperative day. 
Microscopic examination revealed G2 
adenocarcinoma pT4bN0M0 (0/10) with bladder 
infiltration. The follow-up CT, MRI and colonoscopy 
revealed no evidences for local recurrence or distant 
metastases 18 months after the intervention.  
RESuLTS
Eleven posterior and two total pelvic 
exenterations with preservation of urogenital and 
anal sphincters were performed (15,4%). Clear 
margins were achieved in 11 patients (84,6%). Major 
complication (pelvic abscess) was noted in one case 
(7,7%). one-stage bowel restoration was performed 
in two cases with posterior exenteration and two-
stage one - in one patient with total exenteration one 
year later on. The mean follow-up was 35 months. 
one patient died and another was lost to follow-up. 
Among the remaining 11, only two local recurrences 
(18,2%) were noted in the group with posterior 
exenteration after 1 and 2 years, respectively. There 
were no cases with distant metastases. The two cases 
with TPE are still alive and cancer-free, 18 and 13 
months after the operation, respectively. The mean 
survival is 20,5 months, as the follow up is still 
ongoing.
DISCuSSION 
The pelvic exenteration as a method for treat-
ment of advanced pelvic malignancies has been 
first described by Brunschwig in 1948 in attempt to 
achieve clear distal and circimferential margins (R0 
resection). TPE includes removal of the pelvic peri-
toneum, extirpation of the rectum, urinary bladder, 
prostate gland and levator muscles with obturatory 
lymph nodes. In women, the interposition of the gen-
ital system between rectum and urinary bladder of-
ten allows performing of PPE with urinary tract pres-
ervation. The anatomy in men reduces the possibility 
of such procedure and, usually, a TPE is performed. 
After specimen removal, both definitive ureterosto-
my and colostomy are performed together with pel-
vic floor reconstruction. 
The current progress in surgery, radiologi-
cal imaging and critical care led to considerable de-
crease of the mortality rates from 30% to 0-15,6% (6-
8,11-13,15). However, the overall morbidity rates are 
still high and range between 24-55% for primary rec-
tal cancer and 44-78% for recurrent tumours, but the 
major complications requiring intervention are 13-
34% (3,7,11,15). Nevertheless, TPE remains the only 
curative option for the patients with LARC. Report-
ed 5-year survival rates are between 48-66% for pri-
mary rectal cancer and 8-41% for recurrent one (2-
4,14). The 5-year disease-free interval is 52-89% and 
13-38%, respectively (2,3). The mean survival var-
ies between 27,3 and 48,9 months for primary and 
24 for recurrent rectal cancer (6,13). The disease-free 
interval and survival strongly correlate with achieve-
ment of R0 resection and are better for primary rec-
tal cancer (4-6,10-12). In this sense, the proper selec-
fig. 4. Gross specimen of TPe. The probe is into the 
rectovaginal fistula, foley catether is in a prostatic part 
of the urethra. lymph nodes from the base of the inferior 
mesenteric artery (see at the right top). A part of the 
mesorectum resected after specimen removal (see the 
bottom)
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tion of the patients plays a key role. The patients with 
considerable co-morbidity (ASA IV/V), encasement 
of external iliac vessels, side pelvic bones or sacrum 
above S1, paraaortic lymphadenopathy and distant 
metastases are contraindicated for TPE (1,3). Several 
reports deal with the outcome after exenteration sur-
gery for primary LARCs (1-4,9-11,13,14).
The achievement of satisfactory qoL is a very 
important aspect of the modern surgery, besides of 
that of improved survival. A step in this direction for 
these patients is the preservation of the pelvic dia-
phragm with the sphincters.  
A series of 96 patients who underwent TPE with 
preservation at least of one of the both sphincters in 
37,5% of them with mortality 15,6% and major com-
plications in 19.8% was reported (11). The overall 
5-year survival was 41,9%, 5-year disease-free inter-
val was 40,5% with higher survival rates for R0 than 
R1-2 resection (40,9 versus 21,2 months, respectively) 
(11). Five patients with TPE (R0) and preservation of 
the both sphincters with one-stage anastomosis who 
were still alive 13-30 months after operation were re-
ported elesewnere (7). 
In two cases we managed to preserve the uro-
genital diaphragm and anal sphincters achieving 
sufficient distal margin of 3 cm. Both are still alive 
13 and 19 months, respectively, after the intervention 
without evidence of local recurrences or distant me-
tastases. one of them underwent restoration of the 
gastrointestinal integrity.
An additional benefit of sphincter preserving 
TPE is avoiding the possible complications associ-
ated with the pelvic floor reconstruction. on other 
hand, one-stage restoration prolongs the operative 
time and does not allow ‘the test of time’ about pos-
sible recurrences.  
CONCLuSION
In spite of the high morbidity, the multimodal 
approach including TPE is the only curative option 
for LARC patients. Their survival strongly correlates 
with the disease-free interval, so the achievement 
of R0 resection is mandatory. Primary LARC is 
associated with lower morbidity and better survival 
rates than the recurrent ones. The preservation of the 
pelvic diaphragm, when possible, is very important 
for achievement of better qoL and further efforts in 
this direction are justified.   
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